Multiple Sclerosis is a $19 billion market worldwide, and the third most expensive specialty drug spend category. Recently approved Ocrevus is likely to add to cost of treatment... More
Changes to CVS Caremark template formularies effective January 1, 2021 continue our legacy of innovation as well as delivering value and quality care — helping clients save money... More
Purpose-built formulary management and network management strategies from CVS Health are designed to help lower plan costs with minimal member disruption. More
New drugs to treat migraine are approaching approval and could bring relief for many patients, but they portend higher costs. Ongoing monitoring and appropriate utilization... More
Payors can better manage oncology costs by optimizing therapy regimen selection using evidence-based guidelines directly integrated into our proprietary Novologix platform. More
Payors are projected to save on per-member-per-month costs from strategic formulary removals designed to help mitigate the effect of high-cost and hyperinflationary drugs More